New Releases from NCBI BookshelfCemiplimab (cervical cancer): Benefit assessment according to §35a SGB V, : IQWiG Reports – Commission No. A23-36 [Internet].Cemiplimab (cervical cancer): Benefit assessment according to §35a SGB V, : IQWiG Reports – Commission No. A23-36 [Internet].By / July 11, 2024 Post Content
